Compare IDEXX Laboratories, Inc. (IDXX) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while iShares 7-10 Year Treasury Bond ETF trades at $92.89. The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IDXX | IEF | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | — |
52-Week High | $766.68 | $97.99 |
52-Week Low | $526.44 | $92.76 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $92.96 with a modest 0.22% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent institutional activity includes Bank of America increasing its position by 69.8% in Q2 2026. The ETF continues regular dividend distributions, with the latest payment of $0.32 per share in early August 2026.
The outlook for IEF remains challenged by rising Treasury yields and inflation concerns, with technical weakness suggesting continued pressure. However, institutional accumulation and consistent dividend payments provide some support. Key risks include Federal Reserve rate policy uncertainty and Middle East geopolitical tensions impacting oil prices and inflation expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
